News

BlockBeats News, March 18: The U.S. February PPI year-on-year recorded 3.4%, surpassing market expectations of 2.9% and hitting a new high since February last year, with a previous value of 2.90%. The U.S. February PPI month-on-month recorded 0.7%, marking the largest increase since July 2025. (FXStreet)

The issuance scale has been increased compared to the initial plan, reflecting a strong market response to the tech company's financing needs. **Convertible Bond Issuance Details and Market Positioning** The convertible senior notes issued this time will mature in 2029, with a coupon rate set between 0.25% and 0.75%. According to the terms, noteholders have the right to convert their notes into ordinary shares of NEBIUS Group under certain conditions, with the initial conversion premium expected to be between 25% and 30%. The issuance is expected to be settled within this week, with Goldman Sachs and Morgan Stanley acting as joint bookrunners. In the current high-interest-rate environment, tech companies tend to seek low-cost financing through the convertible bond market. Convertible bonds combine debt and equity characteristics, providing issuers with lower interest costs than ordinary bonds, while offering investors the potential opportunity to participate in future share price appreciation. NEBIUS's choice of convertible bond financing aligns with its asset-light, high-growth business model and also avoids the pressure of rapid equity dilution. **Use of Funds and Strategic Layout** NEBIUS Group stated that the raised funds will mainly be used for three purposes: first, to increase investment in artificial intelligence and cloud computing infrastructure; second, to expand emerging market business in Europe and Asia; third, for general corporate purposes, including potential strategic investments and supplementing working capital. The company has recently expanded rapidly in the AI computing power service sector, reaching cooperation agreements with several cloud service providers, and its self-developed AI training chips have entered the testing phase. Market analysts believe that this financing will strengthen NEBIUS's capital strength in the increasingly competitive infrastructure service market, providing ammunition for its technological iteration and regional expansion. **Market Response and Industry Background** After the issuance announcement, NEBIUS rose about 1.5% in pre-market trading on the US stock market. Since the beginning of this year, the company's share price has risen by more than 40%, outperforming most tech peers. Some analysts pointed out that although there are differences in market valuations of tech stocks recently, investors remain optimistic about NEBIUS's differentiated layout in the AI infrastructure sector. The convertible bond market has been active recently, with several tech companies launching similar financings. Industry insiders believe that, against the backdrop of delayed expectations for Federal Reserve rate cuts, convertible bonds have become an important tool for growth companies to balance financing costs and shareholder interests. NEBIUS's successful additional issuance also demonstrates institutional investors' recognition of the long-term prospects of the tech industry. **Risk Warning and Follow-up Observation** However, convertible bond issuance also comes with certain risks. If NEBIUS's share price fails to reach the conversion threshold in the future, the company may face cash flow pressure to repay the principal at maturity. In addition, as competition in AI infrastructure intensifies, capital expenditure efficiency and profitability will become market focal points. Investors can closely monitor NEBIUS's guidance on capital expenditure progress and free cash flow in the next quarterly financial report, as well as the potential impact of specific convertible bond conversion conditions on the equity structure.

This development marks a further breakthrough for the company in the field of minimally invasive spinal surgery. **Technical Platform and Market Positioning** The Ventana® platform is one of Spinal Elements' core product lines, focusing on optimizing spinal fusion procedures through minimally invasive techniques. The newly approved Ventana® a Alif system is designed for anterior lumbar interbody fusion (ALIF), aiming to reduce surgical trauma and enhance patient recovery efficiency. Currently, the global spinal surgery market has an annual scale of approximately $10 billions, with the proportion of minimally invasive procedures increasing year by year. The expansion of the Ventana® platform is expected to help the company capture the fastest-growing segment. **Industry Trends and Competitive Background** In recent years, the spinal surgery sector has accelerated its transformation towards minimally invasive and intelligent approaches. Giants such as Medtronic and Johnson & Johnson have launched similar systems, but the Ventana® platform achieves efficient integration of surgical tools and implants through modular design. This FDA approval coincides with a window period of shortened medical device approval cycles in the United States; since 2023, the average approval time for orthopedic 510(k) has decreased by 15% compared to 2020. **Clinical Progress and Subsequent Plans** The first batch of Ventana® a Alif system surgeries were completed by several medical centers in the United States, with preliminary feedback showing that the average surgery time was reduced by 20% and blood loss was significantly decreased. The company plans to promote this system to more medical institutions in the second half of 2024, while simultaneously conducting European CE certification work. Analysts point out that if clinical results continue to be validated, this product is expected to contribute more than 15% revenue growth for Spinal Elements over the next two years. **Market Response and Strategic Significance** After the announcement, Spinal Elements' stock price rose about 2% in after-hours trading. This platform expansion not only strengthens the company's competitiveness in the field of minimally invasive spinal surgery, but may also accelerate its cooperation or merger negotiations with large medical companies. As population aging drives increased demand for spinal disease treatment, the technological iteration of the Ventana® platform will become a key driver of the company's long-term growth.